CG Oncology (CGON) has just closed out FY 2025 with Q4 revenue of US$2.3 million and a basic EPS loss of US$0.52, alongside a net income loss of US$41.3 million, as the company continues to invest heavily in its pipeline. Over the last twelve months, revenue has summed to US$4.0 million and basic EPS has come in at a loss of US$2.08. This gives investors a clear view of a business that is still in a development phase and running with intentionally thin margins while it pushes its late stage assets forward.

See our full analysis for CG Oncology.

With the headline numbers on the table, the key question now is how this margin profile lines up with the stories investors already follow about CG Oncology and where those narratives might need an update.

Losses Deepen With US$161m LTM Net Loss

• Over the last twelve months, CG Oncology booked US$4.0 million in revenue against a net loss of US$160.995 million and a basic EPS loss of US$2.08, which is wider than the quarterly Q4 loss of US$41.309 million and EPS loss of US$0.52.
• What stands out for a more bullish view is that this very small revenue base of US$4.0 million is paired with late stage development activity, with products in Phase III rising from 2 on an LTM basis at FY 2024 Q4 to 3 by FY 2025 Q4. This heavily supports the idea of a company spending ahead of potential commercialization but also means the current loss profile is entirely tied to pipeline progress rather than established product sales.
  • Supporters who focus on the late stage profile can point to US$160.995 million of LTM net losses as evidence that management is still prioritizing development, yet critics will see the same figure as a reminder that the business is not close to funding itself from the US$4.0 million of LTM revenue.
  • This tension between rising development intensity and minimal current sales is central for investors weighing whether the enlarged LTM loss relative to individual quarterly losses is acceptable for a late stage biotech.

High P/B Of 8.1x Against Thin Revenue

• The stock trades on a P/B of 8.1x compared with 2.5x for the broader US Biotechs industry and 11x for its peer group. It therefore screens as more expensive than the wider industry but cheaper than closer peers, while still being backed by only US$4.0 million of LTM revenue that is described as not meaningful.
• Bears argue that paying 8.1x book for a company with US$160.995 million of LTM net losses and only US$4.0 million of revenue is demanding, and the data supports that concern by showing a five year trend of losses growing at about 38.9% per year even as revenue remains modest.
  • Critics highlight that the stock sits above the broader industry P/B of 2.5x despite lacking meaningful revenue today, so any setback to the development path could make that multiple look stretched against the sector baseline.
  • At the same time, the fact that the P/B is below the peer average of 11x indicates that the market is already applying a discount versus closer comparables, which partially aligns with a cautious view but also suggests some investors are already pricing in the elevated loss profile.

On a day when the stock sits at US$69.18, some investors will want to see how these valuation tensions compare to other late stage biotechs before deciding how much risk they are comfortable taking on solid balance sheet and fundamentals stocks screener (44 results).

DCF Fair Value And Targets Far Above US$69.18

• Against the current share price of US$69.18, the supplied DCF fair value of US$338.28 and a single allowed analyst target of US$87.86 both sit materially higher. The same dataset notes forecasts for earnings growth of about 58.3% per year and revenue growth of about 54.4% per year alongside an expectation of profitability within three years.
• Supporters of a more bullish stance point to this combination of higher DCF fair value and higher analyst target as a sign that models and forecasts see more potential than the current LTM figures suggest, yet the contrast with the present US$160.995 million LTM loss and US$4.0 million in revenue shows that these bullish expectations rest on a major shift in the income statement over the next few years rather than on current fundamentals.
  • On one side, a DCF fair value that is far above the current price and an analyst target of US$87.86 can be read as backing the idea that current losses are temporary, especially with earnings growth projected at about 58.3% per year and profitability expected within three years.
  • On the other side, the same dataset flags shareholder dilution in the past year on top of US$160.995 million of LTM losses, so anyone leaning on these bullish models has to be comfortable with both the financing needs implied by ongoing losses and the gap between today’s revenue base and the growth rates being projected.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on CG Oncology's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Mixed messages in the numbers or a clear pattern emerging? If you want to weigh those risks against the potential rewards yourself, start by checking the 3 key rewards and 2 important warning signs.

See What Else Is Out There

CG Oncology is carrying US$160.995 million in LTM net losses, very limited revenue of US$4.0 million and trades on a relatively full 8.1x P/B.

If that mix of deep losses, thin sales and valuation tension feels like more risk than you want to shoulder right now, check out 72 resilient stocks with low risk scores to focus on companies with steadier financial profiles and potentially calmer ride potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.